key: cord-0930183-2vt70oex
authors: Melidou, Angeliki; Ködmön, Csaba; Nahapetyan, Karen; Kraus, Annette; Alm, Erik; Adlhoch, Cornelia; Mooks, Piers; Dave, Nishi; Carvalho, Carlos; Meslé, Margaux MI; Daniels, Rodney; Pebody, Richard; Tabain, Irena; Botnen, Amanda Bolt; Trebbien, Ramona; Ikonen, Niina; Lyytikäinen, Outi; Wedde, Marianne; Dürrwald, Ralf; Bennett, Charlene; Connell, Jeff; Puzelli, Simona; Facchini, Marzia; Meijer, Adam; Fouchier, Ron A.M.; Vukovikj, Maja; Janchevska, Elizabeta; Bragstad, Karoline; Hungnes, Olav; Komissarov, Andrey; Stolyarov, Kirill; Pozo, Francisco; Casas, Inmaculada; Gonçalves, Ana Rita; Spedaliero, Tania; Moore, Catherine; Cottrell, Simon
title: Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22
date: 2022-04-14
journal: Euro Surveill
DOI: 10.2807/1560-7917.es.2022.27.15.2200255
sha: 18d85ca653a8881a99dac8ce744c5bcba16f934d
doc_id: 930183
cord_uid: 2vt70oex

In the WHO European Region, COVID-19 non-pharmaceutical interventions continued slowing influenza circulation in the 2021/22 season, with reduced characterisation data. A(H3) predominated and, in some countries, co-circulated with A(H1)pdm09 and B/Victoria viruses. No B/Yamagata virus detections were confirmed. Substantial proportions of characterised circulating virus subtypes or lineages differed antigenically from their respective northern hemisphere vaccine components. Appropriate levels of influenza virus characterisations should be maintained until the season end and in future seasons, when surveillance is adapted to integrate SARS-CoV-2.

In the WHO European Region, COVID-19 non-pharmaceutical interventions continued slowing influenza circulation in the 2021/22 season, with reduced characterisation data. A(H3) predominated and, in some countries, co-circulated with A(H1)pdm09 and B/ Victoria viruses. No B/Yamagata virus detections were confirmed. Substantial proportions of characterised circulating virus subtypes or lineages differed antigenically from their respective northern hemisphere vaccine components. Appropriate levels of influenza virus characterisations should be maintained until the season end and in future seasons, when surveillance is adapted to integrate SARS-CoV-2.

This study describes the 2021/22 influenza season in the World Health Organization (WHO) European Region through results of influenza virus detection and typing up to week 10 2022. Viral characterisations reported to The European Surveillance System (TESSy) up to week 4 2022 are also presented, taking into consideration continued implications of the coronavirus disease (COVID-19) pandemic. Based on the WHO Collaborating Centre (CC)'s assessments for the 2022 northern hemisphere (NH) vaccine composition meeting (VCM), similarity of circulating influenza viruses to the 2021/22 NH vaccine components are discussed.

After scant influenza virus circulation in 2020/21, the 2021/22 influenza season started in week 49 2021 in the WHO European Region. In week 2 2022, positivity in sentinel primary care specimens dipped below the epidemic threshold of 10% but rose again above it in weeks 8 to 10 2022 ( Figure 1 ). From week 40 2021 to week 10 2022, 55,049 influenza virus detections from sentinel and non-sentinel sources were reported to TESSy by 50 countries and territories of the Region (Supplement 1). Based on sentinel detections, AH1pdm09 predominated in France [1] . In all the other countries, A(H3) was the major influenza A subtype [1] , co-circulating with A(H1)pdm09 subtype and to a lesser extent type B viruses.

In the 2020 southern hemisphere (SH) and the 2020/21 NH influenza seasons, circulation of influenza viruses was shown to be very limited [2] . In 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-variant waves dominated by Delta (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation: B.1.617.2) and Omicron (Pango: B.1.1.529) coincided with the course of the 2021/22 influenza season in the European Region [3] . Despite an overall increased testing for influenza viruses from sentinel and non-sentinel sources in the Region, which was probably related to enhanced testing for SARS-CoV-2, the total number of influenza virus detections appeared to remain lower than in seasons before the COVID-19 pandemic as shown in Supplement 1. Public health measures aimed at limiting circulation of SARS-CoV-2 likely could have contributed to this reduced positivity. Although sentinel sources continued reporting during the COVID-19 pandemic, data for the 2021/22 influenza season reflected increased testing in some of these sources, while others either did not test or reported on reduced numbers tested (Supplement 1).

European influenza national reference laboratories in the Region collect virological influenza surveillance data, perform virus characterisations and report weekly aggregated and strain-based data to TESSy. The Francis Crick Institute, WHO Collaborating Centre (WHO CC) for Reference and Research on Influenza based in London, United Kingdom (UK), provides laboratories with post-infection ferret antisera for antigenic characterisation using haemagglutination inhibition assays. The Francis Crick Institute WHO CC also provides a list of reference sequences for the assignment of viruses to haemagglutinin (HA) gene clades/subclades following sequencing [4, 5] .

In addition to the Francis Crick Institute WHO CC, there are globally six designated WHO CCs. WHO CCs conduct research and analyses on influenza data or samples, provided by National Influenza Centers (NICs) [6] . Laboratories ship influenza specimens to WHO CCs for further in-depth analyses essential for the WHO Vaccine Composition Meeting (VCM) decisions [7] .

Compared with 2019/20 and 2018/19, seemingly lower amounts of antigenic and genetic characterisation data in 2021/22 were reported to TESSy ahead of the VCM on 25 February 2022 ( Figure 2 ). The WHO European Region Member States reporting characterisations also appeared to be fewer, with the most apparent decrease observed in numbers of countries providing antigenic data. The reason might have been that antigenic characterisation is more laborious. Combinations of reduced human or laboratory resources and biosafety concerns related to the possibility of SARS-CoV-2 coinfection might have also played a role [8] .

Up to week 4 2022, 11 of 50 countries submitted virus genetic characterisation data to TESSy for the 2021/22 season (Table 1) . Antigenic characterisation data were reported to TESSy by six countries. Of all viruses detected, < 1% (144/34,653) were characterised antigenically and 2% (843/34,653) genetically [9] . Ideally, all or at least 10% of the viruses originating from sentinel sources should be genetically characterised [10, 11] . Reported antigenic data ( Figure 2 ) are presented in Table 2 . In their vast majority (134/144, 93%), the antigenic data were not linked with genetic data this season.

Because the antigenic data reported to TESSy were not linked to genetic data, they could not be used for assessing the apparent discrepancies of circulating clade proportions or the similarity of the circulating strains with the respective vaccine virus components. The WHO CC assessments for the 2022 NH VCM were used instead [7] . The characterisations further reported are until week 4 2022. 

Influenza is still circulating above the epidemic threshold in the WHO European Region as at week 10 2022 [9] . While we are in the third year of the COVID-19 pandemic, the public health emergency measures in place have continued to impact the circulation of influenza viruses in 2021/22, although less visibly than in the 2020/21 and 2019/20 seasons. With the lifting of public health measures, influenza detections rose again above the epidemic threshold in week 8 2022, and in the coming weeks influenza viruses may continue to co-circulate with SARS-CoV-2 and other respiratory viruses. Out-ofseason influenza outbreaks cannot be excluded either, particularly with increasing international travel.

The need to prioritise resources for SARS-CoV-2 surveillance during the pandemic likely affected the proportion of influenza viruses that were characterised and their surveillance generally. As a result, the number of countries that reported influenza characterisation data were substantially fewer than in seasons before the COVID-19 pandemic. Our study has some limitations. Characterisation data up to week 4 2022 have been considered and therefore it cannot be excluded that the proportions of circulating influenza types and subtypes may change and that different clades and subclades spread throughout the remainder of the season. As only 22% (11/50) of the countries that report surveillance data to TESSy reported also genetic data, the proportion of different clades may not be generalisable to the WHO European Region as a whole.

NICs play a crucial role in surveillance of influenza being responsible for providing representative specimens to the WHO CC for making VCM recommendations. As influenza presently continues to circulate, NICs should keep up testing and characterising viruses throughout the remainder of current season, while staying vigilant to detect out of season influenza outbreaks as well. Characterisation data from the NH will inform the VCM decisions in the SH VCM that takes place in September─October 2022. The transition towards surveillance systems that integrate influenza, SARS-CoV-2 and other respiratory pathogens may pose challenges to the surveillance systems that need to collect, analyse and timely report data. During this transition period, laboratories will need to ensure that representative specimens for influenza virus detection continue to be collected, and subsequent virus characterisations are performed and reported [10, 11] .

European Centre for Disease Prevention and Control (ECDC)

European Influenza Surveillance Network. Very little influenza in the WHO European Region during the 2020/21 season

Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update -27

European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe (ECDC, WHO/ Europe)

European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe (ECDC, WHO/ Europe)

World Health Organization (WHO). WHO Collaborating Centres and their Terms of Reference. Geneva: WHO

Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO; 2022

WHO European Region influenza surveillance network, WHO European Region Influenza Surveillance Network author list. Virological surveillance of influenza viruses in the WHO European Region in 2019/20 -impact of the COVID-19 pandemic

European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe (ECDC, WHO/ Europe)

COVID-19 surveillance guidance -Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens. Stockholm: ECDC; 2021

End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance. Geneva: WHO; 2022

Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness -United States

recommended-composition-of-influenza-virus-vaccines-foruse-in-the-2022-southern-hemisphere-influenza-season 14. World Health Organization (WHO)

Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. Geneva: WHO; 2020

We express our gratitude to the TESSy data management team, especially Marius Valentin Valcu, for the technical support. We would like to thank Edoardo Colzani and Ole Heuer for reviewing the manuscript, as well as the contributors (Luca Freschi, Olov Svartstrom and Priyanka Nannapaneni, ECDC) and reviewers (Eeva Broberg, Pasi Penttinen, ECDC, Dmitriy Pereyaslov, WHO) of the 'Summary of influenza virus antigenic and genetic characterisations in Europe: data reported by influenza reference laboratories to The European Surveillance System for weeks 40/2021 to week 4/2022', for their valuable comments. We acknowledge all the members of the European region influenza surveillance network for their work on influenza surveillance data collection. We gratefully acknowledge the authors of the HA sequences retrieved from GISAID and used in this study. We would also like to acknowledge the physicians and nurses of sentinel network sites and intensive care units for their contribution in providing respiratory specimens. We would like to thank John McCauley and Rodney Daniels from the WHO CC for reference and research on influenza, Crick Worldwide Influenza Centre, The Francis Crick Institute, London, United Kingdom for their continuous tireless support to the WHO European Region influenza network.

Denmark: We acknowledge regional clinical microbiological departments and sentinel general practitioners for providing samples and data for the national influenza surveillance. We would also like to acknowledge the entire Influenza Surveillance team at Statens Serum Institut, Denmark.England, United Kingdom: We thank all colleagues of the UK Health Security Agency Respiratory Virus Unit and Immunisation and Vaccine Preventable Diseases Division, who support virological and epidemiological surveillance of Influenza. We also thanks Anissa Lakhani, UK Health Security Agency, anissa.lakhani@phe.gov.uk and Conall Watson, UK Health Security Agency, conall.watson@phe.gov.uk Finland: We would like to thank physicians and nurses of sentinel network sites and clinical microbiology laboratories for their contribution in providing respiratory specimens. We also want to thank laboratory personnel in virological team in THL for their excellent technical assistance. Netherlands: we thank epidemiologists, Rianne van Gageldonk, Marit de Lange, Anne Teirlinck, Daphne Reukers and Liz Jenniskens from the RIVM, Bilthoven for weekly assessment of the influenza situation in the Netherlands, epidemiologists Mariëtte Hooiveld and Janneke Hendriksen from Nivel, Utrecht for coordinating the GP sentinel surveillance network and reporting epidemiological data and the GPs and patients in this network for reporting incidence data and taking swabs for virological analysis, the diagnostic hospital and peripheral laboratories in the Netherlands for weekly reports on influenza virus detections and submitting influenza virus positive specimens to Erasmus MC and RIVM, Mark Pronk and Pascal Lexmond from Erasmus MC, Rotterdam and Sharon van den Brink, Lisa Wijsman, Gabriel Goderski, John Sluimer and Chantal Herrebrugh from RIVM, Bilthoven for diagnostics and detailed genetic, antigenic and antiviral susceptibility analysis of influenza virus positive specimens.Norway: We would like to thank all Norwegian medical microbiology laboratories for provision of influenza positive specimens to the NIC as well as data on diagnostic outcomes; the Norwegian Notification System for Infectious Diseases Laboratory Registry for facilitating timely and efficient digital collection of all these influenza testing outcomes and to convey data to the NIC influenza surveillance. We furthermore thank the laboratory staff of the NIC for expert work on influenza virus identification and characterisation as well as data consolidation and analysis. 

Ethical approval was not required for this study as Individuals are not identifiable and only virus data are included.

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.The authors affiliated with the World Health Organization (WHO) are alone responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the WHO.Data are publicly available through www.FluNewsEurope.org and ECDC.

ECDC and WHO internal funds.

None declared.

AM Conceptualisation (lead); writing -original draft (lead); formal analysis (lead); writing -review and editing (equal); CK, KN, AK, EA, CA data analysis (equal) -writing -review and editing (equal); PM, ND, CC, MM, RD and RP review and editing (equal). Members of the network coordinated collection of specimens and epidemiological data, analysed the specimens and provided data to TESSy, reviewed the analysis and approved the final manuscript. All authors contributed to the work, reviewed and approved the manuscript before submission.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.Any supplementary material referenced in the article can be found in the online version.